GHRP-6 Dosage Chart: 100mcg 3x/Day + Hunger Control

GHRP-6 is a synthetic hexapeptide that potently stimulates growth hormone secretion through the ghrelin/GHS receptor — and the most hunger-inducing GHRP available. This is not medical advice.

Research-context information only. GHRP-6 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Community Protocol

GHRP-6 has no standardized clinical dosing protocol — this is a community protocol based on research literature and anecdotal reports.

For the full GHRP-6 peptide profile and comparison guides, see our GHRP-6 Complete Guide and GHRH vs GHRP comparison. For a breakdown of GHRP-6's effects beyond GH release, see our GHRP-6 Benefits Guide.

Cycling Details

GHRP-6 doesn't require a loading phase. Documented protocols begin at 100 mcg once daily (bedtime) during Week 1 to gauge hunger response, then progress to 100 mcg 2-3x daily for weeks 2-16. Three daily injections provide pulsatile GH release mimicking natural secretion patterns.

With prolonged continuous use, ghrelin-receptor secretagogues can show an attenuated GH response; GHRP-6 falls between hexarelin (most affected) and ipamorelin (least). Community protocols run 8-16 weeks on, 4-8 weeks off, described as a way to manage this and let IGF-1 normalize. For how the ghrelin and GHRH peptide families differ on this point, see Do GH Peptides Desensitize the Pituitary?. Documented protocols describe injecting on an empty stomach (at least 2 hours after eating) and waiting 20-30 minutes before consuming food.

Routes of Administration

Subcutaneous (standard): Trial protocols describe subcutaneous injection into the lower abdomen or love handles with daily site rotation. Volume per injection is small (0.04–0.12 mL). Community reconstitution guides commonly reference 29–31 gauge insulin syringes for this volume range. GH release is documented beginning within 5–15 minutes; hunger within 15–30 minutes.

Oral (studied but less effective): GHRP-6 retains some GH-releasing activity orally, though at significantly lower potency than subcutaneous (Bowers et al., 1995).

Reconstitution Quick Reference

Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. 100 mcg / 2,500 = 0.04 mL = 4 units. Swirl gently, refrigerate, use within 28 days.

For step-by-step reconstitution instructions, see the BPC-157 reconstitution guide — same technique applies to all lyophilized peptides.

Ready to buy? Compare verified vendors on our best GHRP-6 sources page (affiliate links — we earn a commission at no extra cost to you), or browse all coupon codes for up to 50% off.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

GHRP-6 has more human clinical data than many research peptides, as it was extensively studied in endocrinology research.

GHRP-6 stimulates GH secretion both in vitro and in vivo through phosphatidylinositol turnover in pituitary somatotroph cells (Lei & Bhargava, 1995). Research established that GHRP-6 requires endogenous hypothalamic GHRH for maximal GH stimulation, explaining the synergistic effects when co-administered with GHRH analogs (Pandya et al., 1998).

Beyond GH release, GHRP-6 has demonstrated cardioprotective and cytoprotective properties independent of GH pathways, acting through GH secretagogue receptor-mediated mechanisms (Berlanga-Acosta et al., 2017).

GHRP-6 activates the ghrelin receptor (GHS-R1a), the same receptor stimulated by endogenous ghrelin. Central administration activates appetite centers in the hypothalamus, including orexin-containing neurons (Wren et al., 2001). The 100 mcg per injection dose is considered near the saturation dose — higher amounts don't meaningfully increase per-bolus GH output.

Stacking Protocols

Community-documented stacking protocols. Doses reflect community-reported and trial-described protocols, not a recommended regimen.

GHRP-6 and GHRH analogs can be combined in the same syringe. Both require empty stomach. Each GHRP has a per-injection ceiling — stacking doesn't bypass individual receptor saturation.

Side Effects & Safety

• Intense hunger — 15-30 minutes post-injection, lasts 30-60 minutes. Most pronounced of all GHRPs
• Water retention — mild, GH-mediated fluid retention in hands/feet
• Cortisol elevation — dose-dependent, more significant than ipamorelin or GHRP-2
• Prolactin elevation — mild at standard doses; more pronounced above 200 mcg
• Blood sugar effects — GH opposes insulin action; trial data document elevated blood glucose as a GH-mediated effect, with diabetic and insulin-resistant subjects identified as a higher-risk population in endocrinology research
• Reduced GH response — prolonged continuous use may attenuate the ghrelin-receptor response; community sources cycle to manage this
• Cancer caution — elevated GH/IGF-1 has raised theoretical oncological concern in the literature; GH-secretagogue trial protocols have systematically excluded subjects with active malignancy

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once GHRP-6 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 5 mg vial + 2 mL BAC water (2.5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 5 mg vial + 5 mL BAC water (1 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.